Krystal Biotech, Inc.
KRYS
$359.36
+2.25%
Krystal Biotech is a commercial-stage biotechnology company focused on developing and commercializing genetic medicines for diseases with high unmet medical needs, leveraging its proprietary HSV-1-based gene therapy platform. The company's lead product, VYJUVEK, is approved for dystrophic epidermolysis bullosa (DEB) and is marketed in the U.S., EU, and Japan, positioning Krystal as a pioneer in topical gene therapy. The current investor narrative centers on the company's rapid revenue growth from VYJUVEK, expansion into new geographic markets, and the potential of its pipeline to address larger indications, which has driven the stock's substantial appreciation over the past year. Recent analyst actions, including multiple Buy ratings and a strong consensus, underscore optimism about the company's commercial execution and future catalysts.…
KRYS
Krystal Biotech, Inc.
$359.36
Related headlines
Investment Opinion: Should I buy KRYS Today?
Rating: Buy. Krystal Biotech is a high-growth biotech with a proven commercial product, VYJUVEK, and a strong pipeline. The consensus rating is Strong Buy with an average target of $385, implying 11.1% upside from the current price of $346.58. The company's revenue growth of 31.95% YoY, gross margin of 92.6%, and net margin of 52.6% underscore its operational excellence. With a PEG ratio of 0.274, the stock is undervalued relative to its growth, and the balance sheet is debt-free with a current ratio of 9.95. Key risks include dependence on a single product and high valuation on sales. This Buy rating would be downgraded if revenue growth decelerates below 20% or if regulatory issues arise. Overall, the stock is fairly valued to slightly undervalued based on growth-adjusted metrics.
Sign up to view all
KRYS 12-Month Price Forecast
Krystal Biotech is fundamentally strong with rapid revenue growth, high profitability, and a solid balance sheet. The valuation is reasonable on a growth-adjusted basis, and analyst sentiment is bullish. However, the stock's high P/S ratio and dependence on a single product warrant caution. I would upgrade my stance if revenue growth accelerates above 40% or pipeline data exceeds expectations, and downgrade if growth falls below 20% or regulatory issues arise.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Krystal Biotech, Inc.'s 12-month outlook, with a consensus price target around $385.00 and implied upside of +7.1% versus the current price.
Average Target
$385.00
0 analysts
Implied Upside
+7.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$284 - $474
Analyst target range
The target price range spans from $284.00 (low) to $474.00 (high), representing a wide spread of 67% from low to high, which reflects significant uncertainty about the company's future prospects. The high target of $474 implies a 36.8% upside, likely assuming continued strong revenue growth and successful pipeline expansion, while the low target of $284 suggests a downside of 18.1%, possibly pricing in competitive pressures or regulatory setbacks. Recent institutional ratings show multiple Buy reiterations from firms like B of A Securities, TD Cowen, and HC Wainwright, with no downgrades, reinforcing the bullish sentiment.
Drowning in data?
Find the real signal!
Bulls vs Bears: KRYS Investment Factors
Krystal Biotech presents a compelling bull case driven by explosive revenue growth, exceptional profitability, and a strong balance sheet, all supported by a bullish analyst consensus. However, the stock's rich valuation on sales and dependence on a single product introduce significant risks. Currently, the bull case has stronger evidence, given the company's proven commercial execution and robust financial metrics. The central tension is whether VYJUVEK's growth can sustain the premium valuation, or if any hiccup in expansion or competition will trigger a re-rating. The resolution of this tension will determine the stock's trajectory over the next 12 months.
Bullish
- Explosive Revenue Growth: Q1 2026 revenue surged 31.95% YoY to $116.36M, with sequential acceleration from $70.28M in Q2 2024. This rapid top-line expansion demonstrates strong commercial uptake of VYJUVEK and successful market penetration.
- Exceptional Profitability: Gross margin stands at 92.6% (TTM), with a net margin of 52.6% and operating margin of 41.5%. The company is highly profitable, generating $55.9M net income in Q1 2026 alone, showcasing efficient operations.
- Undervalued on PEG Ratio: With a PEG ratio of 0.274, the stock trades at a significant discount to its growth rate. This suggests the market is underpricing future earnings growth, offering a compelling value proposition for growth investors.
- Strong Analyst Conviction: The consensus rating is 'Strong Buy' with a mean score of 1.27, and the average price target of $385 implies 11.1% upside. Recent reiterations from B of A Securities, TD Cowen, and HC Wainwright reinforce bullish sentiment.
Bearish
- High Valuation on P/S: The price-to-sales ratio of 18.34x is steep, reflecting high expectations. Any revenue miss could trigger a sharp de-rating, as the market has priced in sustained hyper-growth.
- Dependence on Single Product: VYJUVEK is the sole revenue driver, with no other approved products. This concentration risk means any setback in VYJUVEK's commercial trajectory or competition could severely impact the business.
- Limited Analyst Coverage: Only 8 analysts cover the stock, which may lead to less efficient pricing and higher volatility. The wide target range ($284-$474) indicates significant uncertainty about future prospects.
- Potential Regulatory Hurdles: As a gene therapy, VYJUVEK faces ongoing regulatory scrutiny. Any safety signal or manufacturing issue could lead to restrictions, impacting revenue growth and investor confidence.
KRYS Technical Analysis
Krystal Biotech is in a powerful long-term uptrend, with the stock up 137.87% over the past year, significantly outperforming the S&P 500's 20.48% gain. The current price of $346.58 sits at 90.6% of its 52-week range (between $136.73 and $382.535), indicating the stock is trading near its highs, reflecting strong momentum and investor confidence. The 52-week low of $136.73 was set in late 2025, and the stock has since more than doubled, demonstrating a sustained bullish trend.
Beta
0.54
0.54x market volatility
Max Drawdown
-17.3%
Largest decline past year
52-Week Range
$137-$383
Price range past year
Annual Return
+143.3%
Cumulative gain past year
| Period | KRYS Return | S&P 500 |
|---|---|---|
| 1m | +5.3% | +2.7% |
| 3m | +22.6% | +1.0% |
| 6m | +35.6% | +12.0% |
| 1y | +143.3% | +18.9% |
| ytd | +45.5% | +12.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KRYS Fundamental Analysis
Krystal Biotech's revenue is growing rapidly, with Q1 2026 revenue of $116.357 million, up 31.95% year-over-year from $88.183 million in Q1 2025. The company has consistently increased quarterly revenue from $70.284 million in Q2 2024 to $116.357 million in Q1 2026, showing accelerating growth. This growth is driven by VYJUVEK's commercial success in the U.S. and international expansion, with no revenue segments reported but the product's strong uptake evident in the numbers.
Quarterly Revenue
$116357000.0B
2026-03
Revenue YoY Growth
+31.9%
YoY Comparison
Gross Margin
94.6%
Latest Quarter
Free Cash Flow
$237383000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KRYS Overvalued?
Given that Krystal Biotech is profitable with a trailing EPS of $0.0287, the PE ratio is the primary valuation metric. The trailing PE is 34.82x, while the forward PE is 36.88x, indicating that the market expects slightly higher earnings in the future, but the gap is narrow, suggesting stable growth expectations. The PEG ratio of 0.274 is exceptionally low, implying that the stock is undervalued relative to its growth rate, which is a positive signal for value investors.
PE
34.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 10x~100x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are moderate despite strong profitability. The company's high gross margin of 92.6% and net margin of 52.6% indicate efficient operations, but the reliance on VYJUVEK as the sole revenue source creates concentration risk. With a debt-to-equity ratio of 0.0077, leverage is minimal, but the company's cash burn for R&D and expansion could increase. The current ratio of 9.95 provides ample liquidity, yet any unexpected increase in operating expenses could pressure margins. The trailing PE of 34.82x and forward PE of 36.88x suggest the market expects stable earnings growth, but any earnings miss could lead to a sharp de-rating given the premium valuation.
